hsTnI

1 paper1 finding

Human trial1

Interventions

1

Canagliflozin

downin humans1

1 study

Canagliflozin decreases hsTnI in humans (-10.0% at week 104 (p < 0.05)).
“and -8.3%, -11.9%, and -10.0% for hsTnI at weeks 26, 52, and 104, respectively (all p < 0.05).”
Human trialin older patients with T2DM104 weeks
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
Journal of the American College of Cardiology12 Jun 2017

More on Canagliflozin

Latest

1 in 12 months

Atherosclerosis24 Aug

Circulating biomarkers and polygenic scores for cardiovascular risk prediction in healthy older adults: differential and complementary contributions

Cohort study of 10,433 peopleCardiovascular disease

Journal of the American College of Cardiology12 Jun

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

Randomised trial in 666 peopleCanagliflozin